The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes dwarfism, the company said.
HHS Secretary Kennedy supports Trump's glyphosate order while acknowledging pesticides "are toxic by design" and pose risks to Americans' health.
This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
Since the Chernobyl nuclear disaster in 1986, something has concerned scientists: can exposure to radiation leave marks in someone’s DNA that are passed on to ...
The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...
(“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the ...
The nod allows Hernexeos (zongertinib) to be used as an initial treatment option for NSCLC with HER2-activating mutations in ...
Not all mosquitoes are to blame, however. Every bloodsucking malaria vector comes from those within the group Anopheles leucosphyrus, which encompasses a comparatively small portion of the planet’s ...
BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...
The accelerated approval for patients with HER2 (ERBB2)-mutated disease follows an approval last August for use after prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results